Return to homepagePandemic Pact

Development of a unique in vivo model for long-COVID to test and identify candidate drugs

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.04301E+13

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022
    2025

  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)

  • Principal Investigator

    dr. J den Dunnen PhD

  • Research Location

    Netherlands

  • Lead Research Institution

    Amsterdam UMC Locatie AMC

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Disease models

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

After a coronavirus infection, 10-30% of people continue to have complaints for a long time (months to years). This is called Long-COVID or post-COVID. Worldwide, Long-COVID has a major impact on both the lives of these people and society as a whole, including long-term disability. Unfortunately, there is currently no medicine available. The aim of this project is to develop an animal model for Long COVID. This model gives global research into Long-COVID therapy an enormous boost because it (1) Provides insight into the underlying cause of Long-COVID (2) Provides the opportunity to test possible candidate drugs in the future (3) An objective diagnosis for Long COVID possible (4) Pandemic preparedness supported, because future coronaviruses (just like SARS and MERS) will probably also cause long-term complaints.